Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Evofosfamide (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PATH
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
- 08 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.